[<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors

Hawkins, Douglas S.; Schuetze, Scott M.; Butrynski, James E.; Rajendran, Joseph G.; Vernon, Cheryl; Conrad, Ernest U.; Eary, Janet F.

doi:10.1200/jco.2005.01.7079

Cited by 282 publications

(165 citation statements)

References 33 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…Pretherapy tumor FDG-PET SUV max predicts survival in patients with several types of sarcoma, including liposarcoma, chondrosarcoma, and Ewing's sarcoma [4,5,14]. Synovial sarcoma represents a biologically diverse subtype of soft tissue sarcomas.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Risk Assessment Based on FDG-PET Imaging in Patients with Synovial Sarcoma

Lisle

Eary

O’Sullivan

et al. 2008

Clin Orthop Relat Res

Self Cite

View full text Add to dashboard Cite

Synovial sarcoma generally is associated with poor prognosis. With recent advances in molecular biology, it has become apparent not all synovial sarcomas share the same tumor biology. 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) is useful for risk assessment in several types of sarcomas. We therefore assessed the clinical value of 18 F-FDG-PET-derived maximum standard uptake value (SUV max ) for predicting survival in patients with synovial sarcoma. 18 F-FDG-PET was performed in 44 patients with synovial sarcoma before therapy and resection. SUV max was calculated for each tumor and then evaluated for prognostic usefulness along with metastasis at presentation, tumor grade, histopathologic subtype, age, gender, postsurgical margins, anatomic location, and tumor size for overall survival and progression-free survival. SUV max ranged from 1.2 to 13.0 (median, 4.35). Pretherapy tumor SUV max predicted overall survival and progression-free survival. Patients presenting with a SUV max greater than 4.35 had a decreased diseasefree survival and were therefore at high risk for having local recurrences and metastatic disease.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The SUV max in FDG-PET is a valuable parameter for risk assessment in sarcomas [8,11]. Specifically, initial pretherapy SUV max has been used for prediction of outcome in Ewing's sarcoma, liposarcoma, and chondrosarcoma [4,5,14].…”

Section: Introductionmentioning

confidence: 99%

Risk Assessment Based on FDG-PET Imaging in Patients with Synovial Sarcoma

Lisle

Eary

O’Sullivan

et al. 2008

Clin Orthop Relat Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…Fluorodeoxyglucose PET has been correlated with histologic response to neoadjuvant chemotherapy in ES/ PNET, with a standardized uptake value-2 less than 2.5 being predictive of progression-free survival. 30 In extremity OS, FDG-PET was reported to be only partially correlated with histologic response to neoadjuvant chemotherapy; however, a standardized uptake value-2 less than 2.5 was associated with improved progression-free survival. 31 The PET response to neoadjuvant chemotherapy and potential implications for outcome and subsequent therapy are being investigated prospectively in clinical trials of pediatric sarcoma.…”

Section: Diagnosis and Stagingmentioning

confidence: 99%

Common Musculoskeletal Tumors of Childhood and Adolescence

Arndt¹,

Rose²,

Folpe³

et al. 2012

SciVee

129

View full text Add to dashboard Cite

Osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma are the most common malignant musculoskeletal tumors in children and adolescents. Today, most patients can be cured. Numerous factors have contributed to improved outcome for these patients over the past several decades. These include multidisciplinary care involving oncologists, radiation oncologists, surgeons, pathologists, and radiologists and enrollment of patients in clinical trials. Better understanding of molecular mechanisms of disease have resulted in studies using molecular targets in addition to standard chemotherapeutic agents, which hopefully will lead to better outcomes in the future. Moreover, new orthopedic techniques and devices as well as new technologies in radiation oncology hold promise for better local control of primary tumors and the potential for fewer late adverse effects. Despite this progress, patients must undergo lifelong follow-up for possible late effects of intense chemotherapy and radiation therapy. We review the diagnosis, prognosis, staging, multidisciplinary therapy, new directions in therapy, and long-term complications of treatment for these tumors. For this review, we searched MEDLINE using the terms rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, biology, and humans and limited the search to articles from 2000 to September 2011. Additional references found in these articles were utilized as appropriate, as well as references from the background information in current therapeutic studies of the Children's Oncology Group. The same database and time frame were searched for articles written by leading authorities in the field.

show abstract

“…The detection of viable metastases by positron emission tomography (PET) may be an approach to tackling this problem. [31][32][33][34] In summary, local therapy of the primary tumor and of viable metastases could improve the prognosis in patients with highly advanced, extrapulmonary, metastatic Ewing tumor and warrants further investigation.…”

Section: Local Therapy Disseminated Ewing Sarcoma/haeusler Et Almentioning

confidence: 99%

The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES)

Haeusler

Ranft

Boelling

et al. 2009

Cancer

147

124

View full text Add to dashboard Cite

BACKGROUND:The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES) was investigated.METHODS:We analyzed 120 patients registered into the European Ewing Tumor Working Initiative of National Groups (EURO‐E.W.I.N.G. 99) trial at the trial center of Muenster from 1998 to 2006. Median age was 16.2 years. Local treatment of the primary tumor was surgery in 26 of 120 patients, surgery and radiotherapy in 21 patients, and definitive radiotherapy in 40 patients. For treatment of metastases, 6 of 120 patients received surgery; 9 patients, surgery and radiotherapy; and 33 patients, definitive radiotherapy. Forty‐seven (39%) patients had local treatment of both the primary tumor and metastases, 41 (34%) patients of either the primary tumor or metastases, and 32 (27%) received no local therapy.RESULTS:Event‐free survival (EFS) at 3 years was 0.24 (95% CI, 0.16‐0.33). Univariate analyses demonstrated the impact of local therapy given to the primary tumor: 3‐year EFS was 0.25 with surgery, 0.47 with surgery and radiotherapy, 0.23 with radiotherapy, and 0.13 when no local therapy was administered (P < .001). Three‐year EFS in PDMES was also influenced by the local treatment: surgery, 0.33; surgery and radiotherapy, 0.56; radiotherapy, 0.35; no local therapy, 0.16 (P = .003). Three‐year EFS was 0.39 in patients who received local treatment of both primary tumor and PDMES, compared with 0.17 in patients with any local treatment of either primary tumor or PDMES and 0.14 in patients with no local therapy (P < .001). Multivariate analysis showed absence of local treatment to be the major risk factor (HR = 2.21; P = .027; n = 20).CONCLUSIONS:Local therapy of involved sites is important for patients with PDMES and should complement systemic treatment whenever possible. Cancer 2010. © 2010 American Cancer Society.

show abstract

[¹⁸F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors

Abstract: FDG PET imaging of ESFTs correlates with histologic response to neoadjuvant chemotherapy. SUV2 less than 2.5 is predictive of PFS independent of initial disease stage.

Cited by 282 publications

References 33 publications

Risk Assessment Based on FDG-PET Imaging in Patients with Synovial Sarcoma

Risk Assessment Based on FDG-PET Imaging in Patients with Synovial Sarcoma

Common Musculoskeletal Tumors of Childhood and Adolescence

The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES)

Contact Info

Product

Resources

About

[18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors

Abstract: FDG PET imaging of ESFTs correlates with histologic response to neoadjuvant chemotherapy. SUV2 less than 2.5 is predictive of PFS independent of initial disease stage.

Cited by 282 publications

References 33 publications

Risk Assessment Based on FDG-PET Imaging in Patients with Synovial Sarcoma

Risk Assessment Based on FDG-PET Imaging in Patients with Synovial Sarcoma

Common Musculoskeletal Tumors of Childhood and Adolescence

The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES)

Contact Info

Product

Resources

About

[¹⁸F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors